This article refers to:
Guy B, Noriega F, Ochiai RL, et al. A recombinant live attenuated tetravalent vaccine for the prevention of dengue. Expert Rev Vaccines. 2017:1–13.
http://dx.doi.org/10.1080/14760584.2017.1335201
When the above article was first published online, there was an error in the annotation text under the reference number 33. This has been corrected in both print and online versions as described below.
The two publications above and references 35 and 37 below present key efficacy and safety results over the first 3 to 4 years of Phase III and Phase IIb efficacy trials with CYD-TDV.
Taylor & Francis apologizes for this error.